← Oncology Approval Tracker

FDA DECISION ·

Jideytro

zidesamtinib · Nuvalent

FDA approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic ROS1-positive NSCLC after at least one prior ROS1 tyrosine kinase inhibitor.

LAMPGEN ANALYSIS

Why it matters

The indication adds a ROS1-directed option after prior targeted therapy. ARROS-1 included cohorts with different numbers of prior ROS1 inhibitors, a key distinction when discussing sequencing.

What research teams should watch

Verify ROS1 status and capture each prior inhibitor, progression location and CNS imaging. Avoid drawing comparative rankings from separate single-arm studies.

PRIMARY RECORDS

Sources